Developer docs
API playgroundTry for free, no card

Search company profiles

Edge Animal Health

Full company profile

uuid0002k3k

Namestring
Edge Animal Health
Legal namestring
Edge Animal Health, Inc
Company typeenum
Private
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersNew Jersey, Trinidad & Tobago
HQ citystring
New Jersey
HQ countrystring
Trinidad & Tobago
HQ regionstring
Latin America
Markets served

Serves global market

Keyword5 values
veterinary biotechnology, animal vaccines, CRISPR gene editing, stem cell therapy, animal therapeutics
NAICS code2 codes
  • Veterinary Services541940
  • Support Activities for Animal Production11521
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Veterinary Biopharmaceuticals
No data
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Edge Animal Health is a pre-commercial animal health biotechnology company developing novel therapeutics and vaccines for farm animals and companion animals. Its pipeline is built on gene-engineered vaccines (molecularly attenuated live, live vectored, non-replicating, and mRNA), gene and cell-based therapeutics, and stem cell therapies derived from iPSCs, MSCs, and endocrine cells. Underpinning platforms include an exclusively licensed CRISPR hybrid RNA-DNA (chRDNA) editing platform and advanced delivery technologies (viral vectors, bacterial vectors, encapsulation).

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Edge Animal Health is developing a bi-directional pipeline of novel biotechnological products for veterinary medicine. The core portfolio includes Gene Engineered Vaccines (molecularly attenuated live vaccines, vectored vaccines, and non-replicating vaccines) targeting farm animal health and antibiotic reduction, and Gene Engineered Therapeutics using cell and gene-based platforms enhanced with genetic engineering. The company also develops Stem Cell Therapies derived from iPSCs, MSCs, and endocrine cells for companion animal metabolic and endocrine diseases. Underpinning these products is the CRISPR chRDNA Platform for precision genome editing and Delivery Technologies (viral vectors, bacterial vectors, encapsulation) that enable effective administration of therapeutics and vaccines.

Product and service1 record
1Gene Engineered Vaccines
Partnership8 partners
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaborator and partner. The Gates Foundation supports global health initiatives and Edge's work aligns with their mission to improve animal health in developing regions. Nick Juleff, Ph.D., BVSc, MRCVS, FRSB, Senior Program Officer at the Gates Foundation, serves as an advisor to Edge.

Strategic tierCoreTypeTechnology or Integration
Description

Exclusive license agreement for CRISPR hybrid RNA-DNA (chRDNA) platform for veterinary medicine applications. Ruhi Khan, Chief Business Officer at Caribou Biosciences, serves on Edge's Board of Directors.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research collaborator through University of Georgia Research Foundation (ugarf).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research collaborator. John Dodam, DVM, MS, Ph.D., DACVAA, Professor and Chair, Department of Veterinary Medicine and Surgery at University of Missouri, serves as an advisor to Edge.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Academic research collaborator providing access to cutting-edge genomic research and capabilities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research collaborator supporting Edge's biotechnology development programs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research collaborator contributing to Edge's pipeline development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research collaborator supporting Edge's biotechnology research initiatives.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Edge Animal Health

Veterinary Biopharmaceuticalsedgeanimalhealth.com

Edge Animal Health firmographics

Firmographics
Name
Edge Animal Health
Legal name
Edge Animal Health, Inc
Website
https://edgeanimalhealth.com
Company type
Private
Founded year
2019
Operating status
Operating
Ownership category
akta.pro rank

Where Edge Animal Health is headquartered

Location

Headquarters

HQ city
New Jersey
HQ country
Trinidad & Tobago
HQ region
Latin America

Markets served

Edge Animal Health business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Marketing channels1 record

Edge Animal Health product offering

Product offering

Core offering

Edge Animal Health is a pre-commercial animal health biotechnology company developing novel therapeutics and vaccines for farm animals and companion animals. Its pipeline is built on gene-engineered vaccines (molecularly attenuated live, live vectored, non-replicating, and mRNA), gene and cell-based therapeutics, and stem cell therapies derived from iPSCs, MSCs, and endocrine cells. Underpinning platforms include an exclusively licensed CRISPR hybrid RNA-DNA (chRDNA) editing platform and advanced delivery technologies (viral vectors, bacterial vectors, encapsulation).

Product overview

Edge Animal Health is developing a bi-directional pipeline of novel biotechnological products for veterinary medicine. The core portfolio includes Gene Engineered Vaccines (molecularly attenuated live vaccines, vectored vaccines, and non-replicating vaccines) targeting farm animal health and antibiotic reduction, and Gene Engineered Therapeutics using cell and gene-based platforms enhanced with genetic engineering. The company also develops Stem Cell Therapies derived from iPSCs, MSCs, and endocrine cells for companion animal metabolic and endocrine diseases. Underpinning these products is the CRISPR chRDNA Platform for precision genome editing and Delivery Technologies (viral vectors, bacterial vectors, encapsulation) that enable effective administration of therapeutics and vaccines.

Differentiator

Problem solved

Functional benefit

Products and services

  • Gene Engineered Vaccines

Companies that use Edge Animal Health

Customer profile

Segments2 records

Ideal customer profiles2 records

Edge Animal Health technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Edge Animal Health partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered major and core.

  • Bill & Melinda Gates FoundationmajorStrategic or Co-development PartnerCollaborator and partner. The Gates Foundation supports global health initiatives and Edge's work aligns with their mission to improve animal health in developing regions. Nick Juleff, Ph.D., BVSc, MRCVS, FRSB, Senior Program Officer at the Gates Foundation, serves as an advisor to Edge.
  • Caribou BiosciencescoreTechnology or IntegrationExclusive license agreement for CRISPR hybrid RNA-DNA (chRDNA) platform for veterinary medicine applications. Ruhi Khan, Chief Business Officer at Caribou Biosciences, serves on Edge's Board of Directors.
  • University of GeorgiacoreStrategic or Co-development PartnerAcademic research collaborator through University of Georgia Research Foundation (ugarf).
  • University of MissouricoreStrategic or Co-development PartnerAcademic research collaborator. John Dodam, DVM, MS, Ph.D., DACVAA, Professor and Chair, Department of Veterinary Medicine and Surgery at University of Missouri, serves as an advisor to Edge.
  • Broad InstitutemajorStrategic or Co-development PartnerAcademic research collaborator providing access to cutting-edge genomic research and capabilities.
  • University of DelawarecoreStrategic or Co-development PartnerAcademic research collaborator supporting Edge's biotechnology development programs.
  • University of FloridacoreStrategic or Co-development PartnerAcademic research collaborator contributing to Edge's pipeline development.
  • NC State UniversitycoreStrategic or Co-development PartnerAcademic research collaborator supporting Edge's biotechnology research initiatives.

Recent moves6 records

Expansion highlights5 records

Edge Animal Health competitors and assessment

Company assessment

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

Edge Animal Health financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Edge Animal Health leadership team

Management profile

Number of profiles

Profiles14 records

Edge Animal Health funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Edge Animal Health M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Edge Animal Health

What does Edge Animal Health do?

Edge Animal Health is a pre-commercial animal health biotechnology company developing novel therapeutics and vaccines for farm animals and companion animals. Its pipeline is built on gene-engineered vaccines (molecularly attenuated live, live vectored, non-replicating, and mRNA), gene and cell-based therapeutics, and stem cell therapies derived from iPSCs, MSCs, and endocrine cells. Underpinning platforms include an exclusively licensed CRISPR hybrid RNA-DNA (chRDNA) editing platform and advanced delivery technologies (viral vectors, bacterial vectors, encapsulation).

Is Edge Animal Health a public or private company?

Edge Animal Health is a private company. It is classified as venture growth investor backed and is currently operating.

When was Edge Animal Health founded?

Edge Animal Health was founded in 2019.

Where is Edge Animal Health based?

Edge Animal Health is headquartered in New Jersey, Trinidad & Tobago, in the Latin America region.

Does Edge Animal Health have an API?

No public API is recorded for Edge Animal Health.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales